ZYME · Zymeworks Inc.
$22.86
-1.70% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-76.0
Dividend yield
—
Beta
1.13
Avg volume
1M
Employees
0K
2D change
—
5D change
-0.52%
10D change
-4.92%
30D change
-4.76%
60D change
-8.48%
MTD change
-10.58%
YTD change
-12.65%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ZYME
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-07
Latest call per bank · past 12 months
Wells Fargo
Overweight$37.00
+61.9% vs priceJP Morgan
Overweight$23.00
+0.6% vs priceCitigroup
Buy$22.00
-3.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-07 | Truist Securities | Maintains | Buy | $28.00 → $31.00 |
| 2026-06-30 | Wells Fargo | Maintains | Overweight | $34.00 → $37.00 |
| 2026-06-03 | HC Wainwright & Co. | Reiterates | Buy | $46.00 |
| 2026-05-08 | Wells Fargo | Maintains | Overweight | $33.00 → $34.00 |
| 2026-03-09 | Evercore ISI Group | Maintains | Outperform | $33.00 → $48.00 |
| 2026-03-06 | HC Wainwright & Co. | Maintains | Buy | $32.00 → $46.00 |
| 2026-03-03 | Stifel | Maintains | Buy | $40.00 → $47.00 |
| 2026-03-03 | Leerink Partners | Maintains | Outperform | $52.00 → $58.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 36 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 7.3% below the 50-day MA ($24.38).
- Price vs 200-day MA: Trading 5.3% below the 200-day MA ($23.88).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.30) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($12.02) and high ($28.56).
ZYME Price Chart
Loading chart for ZYME…
Fundamentals
About Zymeworks Inc.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.